Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06040593 · ClinicalTrials.gov registry record
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 927
- Enrollment target
NCT06040593 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 927 participants.
The verdict
NCT06040593 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 927 participants
- Enrollment target
Study Summary
There is a lack of data on clinical and patient factors that are associated with poor survival in patients with HR+ and HER2-low/negative breast cancer treated with neoadjuvant chemotherapy or endocrine therapy. This retrospective, non-interventional study is designed to assess the predictors of clinical outcomes in this patient population. No study drug will be provided as part of this study protocol.
Interventions
- OTHER No drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 927 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2024-02-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06040593
The ClinicalTrials.gov registry entry for NCT06040593 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 927 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No drug is the first listed.
NCT06040593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06040593 about?
NCT06040593 is a clinical study titled "Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer". There is a lack of data on clinical and patient factors that are associated with poor survival in patients with HR+ and HER2-low/negative breast cancer treated with neoadjuvant chemotherapy or endocrine therapy. This retrospective, non-interventional study is designed to assess the predictors of cli...
What is the current status of trial NCT06040593?
This trial is currently completed. The enrollment target is 927 participants. The study started on 2023-07-31. Estimated completion is 2024-02-23.
What interventions are being tested in trial NCT06040593?
The interventions under investigation include: No drug (OTHER).
Who is sponsoring clinical trial NCT06040593?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.